Koos Boeve

199 General discussion and future perspectives V, et al. Optical innovations in surgery. Br J Surg 2015 Jan;102(2):e56-72. 106. Rosenthal EL, Warram JM, de Boer E, Chung TK, Korb ML, Brandwein-Gensler M, et al. Safety and Tumor Specificity of Cetuximab-IRDye800 for Surgical Navigation in Head and Neck Cancer. Clin Cancer Res 2015 Aug 15;21(16):3658-3666. 107. Gao RW, Teraphongphom N, de Boer E, van den Berg NS, Divi V, Kaplan MJ, et al. Safety of panitumumab-IRDye800CW and cetuximab-IRDye800CW for fluorescence- guided surgical navigation in head and neck cancers. Theranostics 2018 Mar 28;8(9):2488-2495. 108. Tasche KK, Buchakjian MR, Pagedar NA, Sperry SM. Definition of “Close Margin” in Oral Cancer Surgery and Association of Margin Distance With Local Recurrence Rate. JAMA Otolaryngol Head Neck Surg 2017 Dec 1;143(12):1166-1172. 109. Nason RW, Binahmed A, Pathak KA, Abdoh AA, Sandor GK. What is the adequate margin of surgical resection in oral cancer? Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2009 May;107(5):625- 629. 110. Braakhuis BJ, Bloemena E, Leemans CR, Brakenhoff RH. Molecular analysis of surgical margins in head and neck cancer: more than a marginal issue. Oral Oncol 2010 Jul;46(7):485-491. 111. Arantes LMRB, De Carvalho AC, Melendez ME, Lopes Carvalho A. Serum, plasma and saliva biomarkers for head and neck cancer. Expert Rev Mol Diagn 2018 Jan;18(1):85-112.